Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland

Real‐World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland

Saved in:

Bibliographic Details
Main Authors:	David Alexander Dickie, Ramil Burden, Alexander C. Miller, Lucy Mackillop, Kevin Heath, Sumit Dutta, Jesse Dawson
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Series:	Journal of Diabetes
Subjects:	persistence real‐world semaglutide type 2 diabetes
Online Access:	https://doi.org/10.1111/1753-0407.70102
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
by: Junko Oya, et al.
Published: (2025-04-01)

Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)

Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01)

Spotlight on the Mechanism of Action of Semaglutide
by: Ilias Papakonstantinou, et al.
Published: (2024-12-01)

From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use
by: Rawan Othman
Published: (2025-08-01)

Contractile Effects of Semaglutide in the Human Atrium
by: Joachim Neumann, et al.
Published: (2024-08-01)

Semaglutide: an emerging treatment option for patients with obesity related HFpEF
by: Sanya Ashraf Khaskheli, et al.
Published: (2024-08-01)

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
by: Mohamad Suki, et al.
Published: (2025-07-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
by: Marine Massy, et al.
Published: (2025-04-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
by: Kenneth Brand, et al.
Published: (2025-04-01)

Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development
by: E. Scott Sills, et al.
Published: (2025-08-01)

Semaglutide and High-Intensity Interval Exercise Attenuate Cognitive Impairment in Type 2 Diabetic Mice via BDNF Modulation
by: Sijie Lai, et al.
Published: (2025-05-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
by: Yang L, et al.
Published: (2024-11-01)

Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin–Lipid Conjugate-Based Nanoparticle
by: Kyeong-Ju Lee, et al.
Published: (2025-04-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide
by: Marcos Osorio Borjas, et al.
Published: (2025-05-01)

Oral semaglutide: the innovation in type 2 diabetes management
by: M. V. Shestakova, et al.
Published: (2021-09-01)

Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway
by: Shuqi Wang, et al.
Published: (2025-05-01)

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice
by: Luyan Sun, et al.
Published: (2025-06-01)

Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan
by: Mohamed Hassanein, et al.
Published: (2022-12-01)

Semaglutide and bariatric surgery induce distinct changes in the composition of mouse white adipose tissue
by: Margo P. Emont, et al.
Published: (2025-05-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Persistence to growth hormone treatment and clinical characteristics of pediatric patients with growth hormone deficiency: A retrospective cohort study of data from the Japan Medical Data Center claims database
by: Sumito Dateki, et al.
Published: (2025-05-01)

Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association
by: Hamid Ahmadi, et al.
Published: (2025-03-01)

Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting
by: Tao Zhao, et al.
Published: (2025-04-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials
by: M. Sh. Shamkhalova, et al.
Published: (2022-07-01)

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years
by: Marwan Sabbagh, et al.
Published: (2025-04-01)

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies
by: Jimmy Wen, et al.
Published: (2025-05-01)

Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01)

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
by: Celestine Odigwe, et al.
Published: (2025-04-01)

Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome
by: Guo S, et al.
Published: (2025-05-01)

Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
by: John L. Petrie, et al.
Published: (2024-10-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity
by: Vasco Sequeira, et al.
Published: (2025-04-01)

Alopecia areata following semaglutide treatment for weight loss: A case report
by: Wasan S. Alzahrani, MBBS, et al.
Published: (2025-09-01)

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01)